Latest news with #ibogaine
Associated Press
22-05-2025
- Health
- Associated Press
Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
DENVER, CO - May 21, 2025 - Ibogaine By David Dardashti, will be hosting a booth at the upcoming Psychedelic Science 2025 conference, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The conference, a premier global gathering for psychedelic research, medicine, policy, and culture, will take place from June 16-20, 2025, at the Colorado Convention Center. Ibogaine By David Dardashti is expected to share profound insights into specific ibogaine treatment protocols tailored to diverse needs, a hallmark of his approach. This information will delve into the nuanced application of ibogaine for a range of conditions, including: Attendees will gain a precise understanding of the ramifications of these specific treatment lengths in relation to an individual's unique needs and circumstances. Dardashti will also illuminate the overall ibogaine experience, explaining its mechanisms and transformative potential with clarity and precision, particularly concerning its application beyond addiction to other challenging health conditions. Known for his work at Ibogaine by David Dardashti, he has long advocated for individualized care, emphasizing the importance of addressing the root causes of various ailments. His presence at Psychedelic Science 2025 offers a significant opportunity for clinicians, researchers, and the wider psychedelic community to learn about these structured and potentially pioneering approaches to ibogaine therapy. About David Dardashti: David Dardashti is a leading expert in ibogaine treatment with extensive experience in developing personalized protocols for addiction, psychological well-being, and other complex health conditions. About Psychedelic Science 2025: Psychedelic Science 2025, hosted by MAPS, is the leading international conference dedicated to the study of psychedelic substances for science, medicine, spirituality, and policy. It brings together experts from around the world to share the latest research and developments in the field. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
News.com.au
17-05-2025
- Politics
- News.com.au
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S.
Wall Street Journal
17-05-2025
- Politics
- Wall Street Journal
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S. Photo: Umit Gulsen
Yahoo
17-05-2025
- Politics
- Yahoo
GOP Lawmaker on His Life-Altering Psychedelic Trip
Rep. Morgan Luttrell opens up about his psychedelic experience in Mexico, where he took ibogaine, a drug that is illegal in the U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
17-05-2025
- Health
- Wall Street Journal
Lawmaker ‘Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It
Morgan Luttrell says he had never smoked anything, let alone tried drugs in his life. So the retired Navy SEAL had to ask a nearby nurse for guidance on how to inhale a psychedelic drug that was part of the final step of an intense three-day experimental therapy. Luttrell had traveled to Mexico in 2018 to take ibogaine, a drug that is illegal in the U.S. but is gaining a reputation within the veteran community as a potential treatment to address complicated conditions like post-traumatic stress disorder. Inhaling a separate drug, called DMT, was the final step in the process.
